carmustine / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carmustine / Generic mfg.
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Active, not recruiting
2
140
Europe
cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2
Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories
Primary Central Nervous System Lymphoma
05/16
05/26
NCT03736616: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Recruiting
2
47
US
Carboplatin, Ifosfamide, Etoposide, VP-16, Rituximab, Rituxan, Carmustine, BCNU, Cytarabine, ARA-C, Melphalan, Autologous HSCT, Autologous Hematopoeitic Stem Cell Transplantation, Acalabrutinib
Swedish Medical Center, Acerta Pharma BV
Diffuse Large B Cell Lymphoma
09/23
09/23
EATL-001, NCT03217643 / 2016-002782-57: CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.

Completed
2
14
Europe
Brentuximab Vedotin
Imagine Institute, Takeda
Enteropathy Associated T-cell Lymphoma
11/22
05/23
NCT02570542: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
2
59
US
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, BEAM chemotherapy, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center, Columbia University, NorthShore University HealthSystem, University of Rochester, Medical College of Wisconsin, University of Nebraska, Sanofi, University Hospitals Seidman Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
10/24
10/24
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
10/24
12/25
XPORT-GBM-029, NCT04421378: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated
1/2
74
Canada, US
Selinexor, KPT-330, XPOVIO, Temozolomide (TMZ), Temodar, Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Karyopharm Therapeutics Inc
Glioblastoma Multiforme
07/23
07/23
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25

Download Options